TyPed - Natalizumab for the treatment of pediatric-onset multiple sclerosis in Portugal

29/03/2019
01/04/2024
EU PAS number:
EUPAS28904
Study
Finalised
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

PRT_TYS_16_11106_TyPed_Protocol_v1_clean8965103509623323372_Redacted

English (371.25 KB - PDF) View document
Study results
Study results

TyPed Study Report_v3_20190125__Redacted

English (838.93 KB - PDF) View document
Study report
Other information